140 related articles for article (PubMed ID: 17327701)
1. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
Di Lorenzo G; Autorino R; De Laurentiis M; Forestieri V; Romano C; Prudente A; Giugliano F; Imbimbo C; Mirone V; De Placido S
Cancer Biol Ther; 2007 Mar; 6(3):313-7. PubMed ID: 17327701
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
3. Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
Al-Chalabi T; Figg WD
Cancer Biol Ther; 2007 Mar; 6(3):318-9. PubMed ID: 17471018
[No Abstract] [Full Text] [Related]
4. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.
Nelius T; Klatte T; de Riese W; Haynes A; Filleur S
Med Oncol; 2010 Jun; 27(2):363-7. PubMed ID: 19365737
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
[TBL] [Abstract][Full Text] [Related]
7. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Figg WD; Li H; Sissung T; Retter A; Wu S; Gulley JL; Arlen P; Wright JJ; Parnes H; Fedenko K; Latham L; Steinberg SM; Jones E; Chen C; Dahut W
BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
Koletsky AJ; Guerra ML; Kronish L
Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
Meng LJ; Wang J; Fan WF; Pu XL; Liu FY; Yang M
J Cancer Res Clin Oncol; 2012 Feb; 138(2):333-9. PubMed ID: 22134838
[TBL] [Abstract][Full Text] [Related]
11. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F
Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
14. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.
Small EJ; Srinivas S; Egan B; McMillan A; Rearden TP
J Clin Oncol; 1996 May; 14(5):1617-25. PubMed ID: 8622080
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
Amato RJ; Hernandez-McClain J; Henary H
Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Mathew P; Logothetis CJ; Dieringer PY; Chen I; Pagliaro LC; Bekele BN; Zhou X; Daliani DD
Clin Genitourin Cancer; 2006 Sep; 5(2):144-9. PubMed ID: 17026803
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
19. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
Fujinami K; Miura T; Takizawa A; Osada Y
Hinyokika Kiyo; 2005 Jan; 51(1):5-8. PubMed ID: 15732332
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
